Chris Knowles Email & Phone Number

New York, NY, US

Laval, Quebec, CA

Accountable for all commercial activities for the billion dollar franchise, Xifaxan. Used to treat Gastrointestinal & Liver disorders. Current year projections are that Xifaxan will exceed over one and a half billion in sales.

Laval, Quebec, CA

Responsible for the commercialization of the Relistor franchise for the treatment of Opioid Induced Constipation (OIC). Successfully launched a new tablet formulation to drive sustained franchise growth in years moving forward.

Dublin, Coolock, IE

• Inherited the mesalamine franchise through acquisition of Warner Chilcott. During this time, developed and implemented strategies to improve prescription trends through close collaboration with sales management while.
• Effectively manage a portfolio valued at over $600 million in net sales, consistently achieving maximum profitability
• US commercial lead for diabetic gastroparesis and mesalamine product development teams (PDT)
• Liaise with patient advocacy groups to leverage policy influence and ensure proper patient access to brands

Dublin, IE

• Successfully prepared and launched Rapaflo® into the BPH marketplace while exceeding corporate expectations. Additional responsibilities included supervising the Urology marketing division consisting of products for.
• Achieved 123% of launch goal and grew Rapaflo® to $130M peak sales
• Developed award-winning digital initiatives to enhance patient adherence through closed-loop marketing strategies
• Worked with KOLs to proactively position a major objection to Rapaflo as a marker of efficacy
• Managed brand teams comprising 3 to 10 marketing professionals, across 4 brands, over a 6-year period

Dublin, Coolock, IE

• Responsible for launch preparations and launching injectable Trelstar® in the prostate cancer market while successfully navigating the buy-and-bill Medicare environment to ensure long term brand viability.
• Exceeded forecasts and achieved double-digit market share, despite being the fifth entrant in a crowded GnRH agonist market and significant changes in Medicare buy-and-bill reimbursement policies
• Instrumental in working with global partners to develop a 6-month formulation of Trelstar®, submission to FDA, negotiating the final approved labeling, and launching the line extension

When I first came on board with Lederle/Wyeth Ayerst Laboratories in 1992, I began my career by selling four products – Suprax (tablets and suspension), Zopsyn, and Biologicals – to multiple specialities.Although I was new to the business, my performance was exemplary.Key Accomplishments:✔ Ranked first in Mid-Atlantic Region for “Key Lederle Products”✔.